Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
18 01 2020
Historique:
received: 24 07 2019
revised: 11 10 2019
accepted: 12 11 2019
entrez: 20 1 2020
pubmed: 20 1 2020
medline: 6 2 2020
Statut: ppublish

Résumé

Sepsis is life-threatening organ dysfunction due to a dysregulated host response to infection. It is considered a major cause of health loss, but data for the global burden of sepsis are limited. As a syndrome caused by underlying infection, sepsis is not part of standard Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) estimates. Accurate estimates are important to inform and monitor health policy interventions, allocation of resources, and clinical treatment initiatives. We estimated the global, regional, and national incidence of sepsis and mortality from this disorder using data from GBD 2017. We used multiple cause-of-death data from 109 million individual death records to calculate mortality related to sepsis among each of the 282 underlying causes of death in GBD 2017. The percentage of sepsis-related deaths by underlying GBD cause in each location worldwide was modelled using mixed-effects linear regression. Sepsis-related mortality for each age group, sex, location, GBD cause, and year (1990-2017) was estimated by applying modelled cause-specific fractions to GBD 2017 cause-of-death estimates. We used data for 8·7 million individual hospital records to calculate in-hospital sepsis-associated case-fatality, stratified by underlying GBD cause. In-hospital sepsis-associated case-fatality was modelled for each location using linear regression, and sepsis incidence was estimated by applying modelled case-fatality to sepsis-related mortality estimates. In 2017, an estimated 48·9 million (95% uncertainty interval [UI] 38·9-62·9) incident cases of sepsis were recorded worldwide and 11·0 million (10·1-12·0) sepsis-related deaths were reported, representing 19·7% (18·2-21·4) of all global deaths. Age-standardised sepsis incidence fell by 37·0% (95% UI 11·8-54·5) and mortality decreased by 52·8% (47·7-57·5) from 1990 to 2017. Sepsis incidence and mortality varied substantially across regions, with the highest burden in sub-Saharan Africa, Oceania, south Asia, east Asia, and southeast Asia. Despite declining age-standardised incidence and mortality, sepsis remains a major cause of health loss worldwide and has an especially high health-related burden in sub-Saharan Africa. The Bill & Melinda Gates Foundation, the National Institutes of Health, the University of Pittsburgh, the British Columbia Children's Hospital Foundation, the Wellcome Trust, and the Fleming Fund.

Sections du résumé

BACKGROUND
Sepsis is life-threatening organ dysfunction due to a dysregulated host response to infection. It is considered a major cause of health loss, but data for the global burden of sepsis are limited. As a syndrome caused by underlying infection, sepsis is not part of standard Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) estimates. Accurate estimates are important to inform and monitor health policy interventions, allocation of resources, and clinical treatment initiatives. We estimated the global, regional, and national incidence of sepsis and mortality from this disorder using data from GBD 2017.
METHODS
We used multiple cause-of-death data from 109 million individual death records to calculate mortality related to sepsis among each of the 282 underlying causes of death in GBD 2017. The percentage of sepsis-related deaths by underlying GBD cause in each location worldwide was modelled using mixed-effects linear regression. Sepsis-related mortality for each age group, sex, location, GBD cause, and year (1990-2017) was estimated by applying modelled cause-specific fractions to GBD 2017 cause-of-death estimates. We used data for 8·7 million individual hospital records to calculate in-hospital sepsis-associated case-fatality, stratified by underlying GBD cause. In-hospital sepsis-associated case-fatality was modelled for each location using linear regression, and sepsis incidence was estimated by applying modelled case-fatality to sepsis-related mortality estimates.
FINDINGS
In 2017, an estimated 48·9 million (95% uncertainty interval [UI] 38·9-62·9) incident cases of sepsis were recorded worldwide and 11·0 million (10·1-12·0) sepsis-related deaths were reported, representing 19·7% (18·2-21·4) of all global deaths. Age-standardised sepsis incidence fell by 37·0% (95% UI 11·8-54·5) and mortality decreased by 52·8% (47·7-57·5) from 1990 to 2017. Sepsis incidence and mortality varied substantially across regions, with the highest burden in sub-Saharan Africa, Oceania, south Asia, east Asia, and southeast Asia.
INTERPRETATION
Despite declining age-standardised incidence and mortality, sepsis remains a major cause of health loss worldwide and has an especially high health-related burden in sub-Saharan Africa.
FUNDING
The Bill & Melinda Gates Foundation, the National Institutes of Health, the University of Pittsburgh, the British Columbia Children's Hospital Foundation, the Wellcome Trust, and the Fleming Fund.

Identifiants

pubmed: 31954465
pii: S0140-6736(19)32989-7
doi: 10.1016/S0140-6736(19)32989-7
pmc: PMC6970225
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

200-211

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM119519
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007044
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007287
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007820
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access Article under the CC BY 4.0 licence. Published by Elsevier Ltd.. All rights reserved.

Références

Lancet. 2018 Nov 10;392(10159):1684-1735
pubmed: 30496102
JAMA. 2018 Jul 24;320(4):358-367
pubmed: 30043064
JAMA. 2017 Oct 3;318(13):1241-1249
pubmed: 28903154
BMC Med. 2018 Feb 8;16(1):13
pubmed: 29415741
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
Ann Intensive Care. 2017 Dec;7(1):19
pubmed: 28220453
PLoS One. 2011;6(6):e14817
pubmed: 21674036
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
JAMA. 2014 Jul 2;312(1):90-2
pubmed: 24838355
Lancet Infect Dis. 2017 Nov;17(11):1180-1189
pubmed: 28826588
Crit Care Med. 2017 Mar;45(3):486-552
pubmed: 28098591
Crit Care Med. 2007 May;35(5):1244-50
pubmed: 17414736
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Crit Care Med. 2001 Jul;29(7):1303-10
pubmed: 11445675
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care. 2018 Apr 13;22(1):92
pubmed: 29653553
JAMA. 2014 Apr 2;311(13):1308-16
pubmed: 24638143
BMC Infect Dis. 2014 Dec 21;14:3863
pubmed: 25528662
Am J Respir Crit Care Med. 2017 Oct 1;196(7):856-863
pubmed: 28345952
N Engl J Med. 2003 Feb 13;348(7):651-6
pubmed: 12584377
Lancet Respir Med. 2018 Mar;6(3):223-230
pubmed: 29508706
Med Care. 2014 Jun;52(6):e39-43
pubmed: 23001437
Crit Care Med. 2013 May;41(5):1167-74
pubmed: 23442987
Infect Dis (Lond). 2019 Jan;51(1):38-49
pubmed: 30460859
N Engl J Med. 2017 Jun 8;376(23):2235-2244
pubmed: 28528569
Intensive Care Med. 2018 Jun;44(6):925-928
pubmed: 29675566
Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701
pubmed: 12433670
Lancet. 2017 Jul 15;390(10091):231-266
pubmed: 28528753
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Lancet. 2010 Oct 16;376(9749):1339-46
pubmed: 20934212
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Intensive Care Med. 2018 Jul;44(7):1071-1080
pubmed: 29846748
N Engl J Med. 2003 Apr 17;348(16):1546-54
pubmed: 12700374
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
Open Forum Infect Dis. 2018 Nov 19;5(12):ofy313
pubmed: 30555852

Auteurs

Kristina E Rudd (KE)

Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Sarah Charlotte Johnson (SC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Kareha M Agesa (KM)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Katya Anne Shackelford (KA)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Derrick Tsoi (D)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Daniel Rhodes Kievlan (DR)

Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Danny V Colombara (DV)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Kevin S Ikuta (KS)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.

Niranjan Kissoon (N)

Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.

Simon Finfer (S)

The George Institute for Global Health, University of New South Wales, Newtown, NSW, Australia.

Carolin Fleischmann-Struzek (C)

Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.

Flavia R Machado (FR)

Anesthesiology, Pain and Intensive Care Department, Federal University of São Paulo, São Paulo, Brazil.

Konrad K Reinhart (KK)

Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany; Anästhesiologie mit Sp operative Intensivmeidzin, Charité University Medical Center Berlin, Berlin, Germany.

Kathryn Rowan (K)

Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC), London, UK; Faculty of Public Health & Policy linked to the Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.

Christopher W Seymour (CW)

Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

R Scott Watson (RS)

Department of Pediatrics, University of Washington, Seattle, WA, USA; Pediatric Critical Care Medicine, Seattle Children's Hospital, Seattle, WA, USA.

T Eoin West (TE)

Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA, USA.

Fatima Marinho (F)

Institute of Advanced Studies, University of São Paulo, São Paulo, Brazil.

Simon I Hay (SI)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.

Rafael Lozano (R)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.

Alan D Lopez (AD)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; University of Melbourne, Melbourne, QLD, Australia.

Derek C Angus (DC)

Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Christopher J L Murray (CJL)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.

Mohsen Naghavi (M)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. Electronic address: nagham@uw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH